Annexon flagged an ASRS 2026 presentation on Phase 2 ARCHER data for vonaprument in geographic atrophy, highlighting baseline factors tied to BCVA 15-letter loss.
Results are intended to guide patient selection for the ongoing Phase 3 ARCHER II trial, with topline pivotal data expected in Q4 2026.
Vonaprument is a non-pegylated Fab designed to block C1q, targeting neurodegeneration pathways in dry age-related macular degeneration with geographic atrophy.
ANNX•
